Skip to main content
Premium Trial:

Request an Annual Quote

Acquisitions Help Clinical Data Post 39-Percent Revenue Growth in Fiscal Q3

NEW YORK, Feb. 14 (GenomeWeb News) - Clinical Data posted a 39-percent surge in revenues durinig its fiscal third quarter due to an increased asset base from the acquisitions of GenaissanceIcoria, and Electa Lab, the company said today.


Revenues for the three months ended Dec. 31, 2005, increased to $19.9 million from $14.3 million in the year-ago period.


The company reported a net loss for the third quarter of $42.8 million, compared with a net income of $1 million in Q3 2004. Specifically, it recognized $40.1 million in aggregate purchased in-process R&D expenses related to the development of biomarkers for vilazodone and clozapine, two of the leading products in development acquired with Genaissance.


Additional data, including cash and cash equivalents and total R&D spending, will be released later today, Clinical Data said.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.